BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moro A, Mehta R, Sahara K, Tsilimigras DI, Paredes AZ, Farooq A, Hyer JM, Endo I, Shen F, Guglielmi A, Aldrighetti L, Weiss M, Bauer TW, Alexandrescu S, Poultsides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Soubrane O, Koerkamp BG, Sasaki K, Pawlik TM. The Impact of Preoperative CA19-9 and CEA on Outcomes of Patients with Intrahepatic Cholangiocarcinoma. Ann Surg Oncol 2020;27:2888-901. [DOI: 10.1245/s10434-020-08350-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhao C, He C, Lu J, Huang X, Chen C, Lin X. Progression Patterns and Post-Progression Survival in Recurred Intrahepatic Cholangiocarcinoma Patients: A Novel Prognostic Nomogram Based on Multicenter Cohorts. Front Oncol 2022;12:832038. [DOI: 10.3389/fonc.2022.832038] [Reference Citation Analysis]
2 Lang SA, Bednarsch J, Joechle K, Amygdalos I, Czigany Z, Heij L, Ulmer TF, Neumann UP. Prognostic biomarkers for cholangiocarcinoma (CCA): state of the art. Expert Rev Gastroenterol Hepatol 2021;15:497-510. [PMID: 33970740 DOI: 10.1080/17474124.2021.1912591] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Serifis N, Tsilimigras DI, Cloonan DJ, Pawlik TM. Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma. Hepat Med 2021;13:93-104. [PMID: 34754247 DOI: 10.2147/HMER.S278136] [Reference Citation Analysis]
4 Zhang X, Zhou Y, Wu Z, Peng W, Li C, Yan L, Yang J, Wen T. Double-Negative α-Fetoprotein and Carbohydrate Antigen 19-9 Predict a Good Prognosis in Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis. Clin Transl Gastroenterol 2021;12:e00425. [PMID: 34751187 DOI: 10.14309/ctg.0000000000000425] [Reference Citation Analysis]
5 Ntanasis-Stathopoulos I, Tsilimigras DI, Gavriatopoulou M, Schizas D, Pawlik TM. Cholangiocarcinoma: investigations into pathway-targeted therapies. Expert Rev Anticancer Ther 2020;20:765-73. [PMID: 32757962 DOI: 10.1080/14737140.2020.1807333] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Qiu H, Liu C, Huang M, Shen S, Wang W. Prognostic Value of Combined CA19-9 with Aspartate Aminotransferase to Lymphocyte Ratio in Patients with Intrahepatic Cholangiocarcinoma After Hepatectomy. Cancer Manag Res 2021;13:5969-80. [PMID: 34377017 DOI: 10.2147/CMAR.S320380] [Reference Citation Analysis]
7 Pavicevic S, Reichelt S, Uluk D, Lurje I, Engelmann C, Modest DP, Pelzer U, Krenzien F, Raschzok N, Benzing C, Sauer IM, Stinzing S, Tacke F, Schöning W, Schmelzle M, Pratschke J, Lurje G. Prognostic and Predictive Molecular Markers in Cholangiocarcinoma. Cancers 2022;14:1026. [DOI: 10.3390/cancers14041026] [Reference Citation Analysis]
8 Hewitt DB, Brown ZJ, Pawlik TM. Surgical management of intrahepatic cholangiocarcinoma. Expert Rev Anticancer Ther 2021;:1-12. [PMID: 34730474 DOI: 10.1080/14737140.2022.1999809] [Reference Citation Analysis]
9 Ma B, Meng H, Shen A, Ma Y, Zhao D, Liu G, Zheng S, Tian Y, Zhang W, Li Q, Li S. Prognostic Value of Inflammatory and Tumour Markers in Small-Duct Subtype Intrahepatic Cholangiocarcinoma after Curative-Intent Resection. Gastroenterol Res Pract 2021;2021:6616062. [PMID: 33833794 DOI: 10.1155/2021/6616062] [Reference Citation Analysis]